In recent years, the relationship between IgE and chronic urticaria (CU) has gradually become a hot spot. As an expert in the field of IgE, Creative Biolabs is committed to providing professional IgE and CU research related information and customized solutions to advance your project.
Introduction of CU
Urticaria is a common skin disease exhibiting with wheals, angioedema or both. Urticaria is a localized edema reaction due to the expansion of small blood vessels in the skin and mucous membranes and increased permeability. Individual urticaria is short-lived and has no secondary skin damage, such as scaling or exfoliation. Skin redness and itching are key features of the differential diagnosis. Urticaria can be divided into acute and chronic spontaneous urticaria according to clinical manifestations. According to the current international classification, CU can be further classified as chronic spontaneous urticaria (CSU) lacking clear predisposing factors and chronic predisposing urticaria (CINDU) accompanied by clear predisposing factors that can trigger symptoms repeatedly.
IgE in CU
In urticaria, changes in the value and behavior of basophils accompanied by changes in the expression and function of signal molecules and abnormal activation of exogenous coagulation pathways are hypotheses about the pathology of urticaria. In addition, scientists infer that CU may be an immune-mediated inflammatory disease, which is related to changes in the cytokine-chemokine network caused by immune disorders. It is worth noting that the central location of mast cells and their inappropriate activation and degranulation are the key pathological mechanisms, which can be induced by cross-linking reactions with specific IgE antibodies to allergens. The same pathological mechanisms may be interrelated with each other. An in-depth understanding of the complexity of pathogenesis is conducive to the treatment of CU.
Treatment of CU
Nowadays, there are multiple strategies that can be used to treat CU. In the actual application process, some unfavorable factors should be avoided, such as non-steroidal anti-inflammatory drugs, pressure, alcohol and local friction. Non-sedating antihistamines as first-line therapy is an effective strategy, and such drugs can also be used in combination with oral corticosteroids. In recent years, more and more evidence has illustrated that targeting IgE with antibodies provides a promising tool. Although several anti-IgE antibodies have been developed, only one has been approved for use. Randomized clinical trials and data demonstrate that the approved monoclonal antibody is effective and safe for the symptomatic cure of CSU.
Fig.1 Mechanisms of various drugs for chronic spontaneous urticaria. (Wedi, 2021)
Based on our rich experience and professional scientists in IgE and CU research, we are very pleased to provide products and services related to IgE development. Please contact us for more details.
- Wedi, B.; Traidl, S. Anti-IgE for the Treatment of Chronic Urticaria. ImmunoTargets and therapy. 2021, 10: 27.
!! For Research Use Only. Our products and services are NOT intended for diagnostic or therapeutic applications.